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Abstract
Background/aims—Retinal degenerations
are a leading cause of blindness for which
there are currently no eVective treat-
ments. This has stimulated interest in the
investigation of gene therapy strategies for
these diseases in a variety of animal mod-
els. A number of attempts have been made
to prevent photoreceptor loss in the rd
mouse model of retinal degeneration
using adenoviral vectors containing either
a copy of the missing functional gene or a
gene encoding either a neurotrophic fac-
tor or an antiapoptotic factor. The authors
have previously demonstrated that in-
traocular administration of an adenoviral
vector containing a â galactosidase gene
(AV.LacZ) results in an immune response
to viral gene products and â galactosidase.
Here the eVect of the immune response on
retinal degeneration is examined.
Methods—Juvenile rd mice were injected
intravitreally with AV.LacZ and a pro-
portion were depleted of either CD4+ or
CD8+ T cells or both. Control animals
were injected with PBS. The mice were
sacrificed 10 and 20 days post-injection
and their eyes embedded in paraYn wax
and sectioned.
Results—10 days after intravitreal injec-
tion of AV.LacZ, the outer nuclear layer
contains an average of 2.5 rows compared
with 1.5 in PBS injected animals
(p<0.005). The protective eVect of
AV.LacZ is negated by immune suppres-
sion and does not extend beyond 20 days.
Conclusion—An immune response to vec-
tor and transgene products is able to slow
degeneration in the rd mouse. This phe-
nomenon should be taken into account
when analysing the degeneration in the rd
mouse following gene transfer.
(Br J Ophthalmol 2001;85:341–344)
Retinal degeneration is a common cause of
blindness for which there is still no treatment.
Of all the retinal degenerations, retinitis
pigmentosa (RP) is the best characterised.1 It
has an overall prevalence of up to 1 in 3000
and leads to progressive loss of vision, initially
manifesting as night blindness and reduction of
the peripheral visual field, and later involving
central vision. RP is clinically and genetically
heterogeneous with 28 mapped loci and 11
identified genes, seven of which are expressed
exclusively in photoreceptor cells.2–8 A number
of well characterised animal models with gene
defects analogous to those found in humans
have increased our understanding of these dis-
eases and also provide models to test treatment
strategies. The retinal degeneration (rd) mouse
is perhaps the most extensively investigated
animal model for RP.9 It is homozygous for a
spontaneously occurring null mutation in the
gene which encodes the â subunit of rod
specific cyclic GMP phosphodiesterase
(âPDE). Analogous mutations in the gene
encoding âPDE in humans results in auto-
somal recessive RP. The lack of functional
PDE in the rd mouse results in a rapid and
severe degeneration. Photoreceptors are lost
within 1 week of birth, with 50% loss by 2
weeks and almost complete loss by 4 weeks. As
in other models of retinal degeneration, it has
been demonstrated that photoreceptors are
lost through an apoptotic mechanism.10 Het-
erozygous rd mice are phenotypically indistin-
guishable from wild type animals.
Three diVerent gene therapy strategies have
been followed in attempts to slow the degen-
eration in the rd mouse—introduction of a
functional copy of the âPDE gene to photore-
ceptor cells in order to test the eYcacy of gene
replacement therapy11–13; introduction of addi-
tional copies of the bcl-2 gene to photoreceptor
cells in order to block apoptosis directly14; and,
finally, introduction of genes encoding secreted
neurotrophic factors to cells in the anterior
segment of the eye15 in order to support degen-
erating photoreceptors by indirectly blocking
apoptosis. The latter two strategies while not
capable of improving vision may help maintain
it by preserving rods and therefore indirectly
preserving cones which do not have the rod
specific enzyme defect but are nevertheless
eventually lost. In vitro16 and in vivo17 data sug-
gest that diVusible trophic factors released by
rods promote cone cell survival.
Adenoviral vectors (AV) have been widely
used for gene transfer to the eye and there have
been a number of reports of delayed retinal
degeneration in rd mice following subretinal
delivery of AV and AV encapsulated vectors
carrying a gene encoding either âPDE11 13 or
Bcl-214 or intravitreal delivery of an AV vector
carrying a gene encoding ciliary neurotrophic
factor (CNTF).15 We have previously demon-
strated that intraocular administration of an
adenoviral vector containing a â galactosidase
(lacZ) gene results in retinal inflammation and
a T cell mediated immune response to viral
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and â galactosidase products.18 Furthermore,
immune suppression by administration of T
cell specific monoclonal antibodies prolonged
the duration of lacZ gene expression. In order
to determine the eVects of an immune
response to adenoviral vector and transgene
products on retinal degeneration, we intravit-
really injected rd mice with an AV vector
carrying a lacZ reporter gene with and without
immune suppression. Our results suggest that
the immune response itself is able to slow
degeneration in the rd mouse.
Materials and methods
ANIMALS AND INJECTIONS
The recombinant vector used was an E1
deleted recombinant human 5a adenoviral vec-
tor, pXCXRBb, containing a lacZ reporter
gene driven by a rous sarcoma virus LTR pro-
moter (AV.LacZ). This was a kind gift from Dr
A P Byrnes, Department of Molecular Micro-
biology and Immunology, Johns Hopkins Uni-
versity School of Public Health, USA and has
been previously described.19 Intravitreal injec-
tions were carried out in 12 day old rd mice
(C3H, Harlan Olac Ltd, UK). Mice were
anaesthetised by intraperitoneal injection of
0.2 ml Hypnorm (Janssen Pharmaceutical Ltd,
Oxford), and Hypnovel (Roche, Welwyn Gar-
den City) mixed 1:1:6 with distilled water. The
eyes were protruded by gentle pressure on the
animal’s mandible. Once the eye had been
proptosed, it was held in position by a rubber
sleeve which was placed around the eye with a
pair of forceps. The pressure of the rubber
sleeve on the eye was always moderate and did
not block the circulation. The eye was
additionally stabilised by holding an extraocu-
lar muscle with a pair of fine forceps. The tip of
a 1.5 cm, 34 gauge needle (Hamilton, Switz)
was tunnelled transclerally through the pars
plana into the vitreous, in parallel with the lim-
bus. Either 1 µl of phosphate buVered saline
(PBS) or 1 µl of Av.LacZ (1 ×106 pfu) was
injected. Only one eye per animal was proc-
essed. Some of the animals were also depleted
of T cells by intraperitoneal injection at of 250
µg CD4 (YTS 191) and/or CD8 (Yts 169)
specific monoclonal antibodies20 1 day before
intravitreal injection.
HISTOLOGY
Animals were sacrificed 10 and 20 days
post-injection. Eyes were removed, fixed in
10% neutral buVered formalin, embedded in
paraYn wax using a routine protocol, and sec-
tioned to the level of optic nerve head (ONH).
Only sections taken close to either side of the
ONH were evaluated to ensure that areas of
retinas of normally equivalent thicknesses were
compared. The 5 µm sections were counter-
stained with haematoxylin and eosin. Two
independent observers assessed the number of
rows of photoreceptor nuclei in the outer
nuclear layer (ONL) of several sections from
each eye. The scoring system was as follows: 0,
a sparse row of photoreceptors; 1, a single row
of photoreceptors; 2, between one and two
rows of photoreceptors; 3, between two and
three rows of photoreceptors, and so on. For
animals sacrificed 10 days post-injection,
between six and 12 eyes were analysed per
experimental group while for animals sacri-
ficed 20 days post-injection, between 10 and
20 eyes were analysed. The standard error of
the mean ONL score were calculated and a
non-paired, two tailed Mann-Whitney U test
was used to calculate significance.
Results
Litters of 12 day old rd mice were injected
intravitreally with AV.LacZ. The injections
were performed intravitreally rather than sub-
retinally since subretinal injection results in a
partial detachment with localised transduction
and in subsequent analysis it would be more
diYcult to compare equivalent areas. Twelve
day old animals were chosen because the eyes
are large enough to allow injections of consist-
ent quality. In very young mice it is diYcult to
inject the eyes without causing damage to the
lens. In order to control for slight diVerences in
age of animals, litters of rd mice were divided
randomly between the diVerent experimental
groups. Animals were injected with AV.LacZ,
of which a proportion were depleted of either
CD4+ or CD8+ T cells or both. Control
animals were injected with PBS. The mice
were sacrificed after 10 or 20 days post-
injection and the eyes embedded in paraYn
wax and sectioned. Only sections taken close to
either side of the optic nerve head were evalu-
ated to enable us to compare retinas of
normally equivalent thicknesses (Fig 1). The
outer nuclear layer (ONL) of the retina
contains photoreceptor cell nuclei. At 22 days
in a normal mouse retina the ONL is 8–10
rows thick whereas in the rd mouse the ONL is
reduced to one row. In 22 day old rd mice, 10
days after intravitreal injection of AV.LacZ, the
ONL contains an average of 2.5 rows com-
pared with 1.5 in PBS injected animals (Figs 2
and 3), p<0.005. The protective eVect of
AV.LacZ is negated by immune suppression. In
animals injected with AV.LacZ and depleted of
both CD4+ and CD8+ T cells there was no
statistically significant diVerence between the
Figure 1 Eyes were sectioned to the level of optic nerve head (ONH) and only sections
taken close to either side of the ONH were evaluated to ensure that retinas of normally
equivalent thicknesses were compared. A 5 µm paraYn wax section counterstained with
haematoxylin and eosin (10× objective) taken from 22 day old rd mouse 10 days after
intravitreal injection of 1 µl of PBS.
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ONL thickness compared with animals in-
jected with only PBS. Depletion of just one
type of these T cells did not alter the eVect of
AV.LacZ. This is consistent with our previous
observation that depletion of both CD4 and
CD8 cells was required for suppression of
immune responses following ocular AV admin-
istration.18 Twenty days after injection, the
ONL was slightly thicker in AV.LacZ injected
animals compared with controls. However, the
diVerences were not statistically significant
(data not shown).
Discussion
Immune responses following intravitreal and
subretinal administration of adenoviral vectors
have been reported previously. In this study we
have demonstrated that a T cell mediated
immune response is able to alter the course of
retinal degeneration in the rd mouse. Earlier
studies have shown that sham PBS injections
are able to slow degeneration in the rdy rat reti-
nal degeneration.21 This phenomenon appears
to be due to stimulation of growth factors
which promote photoreceptor survival. Al-
though it has been shown in this and other
studies22 that intraocular PBS injections do not
have a significant eVect on photoreceptor
survival in the rd mouse, we have demonstrated
here that adenoviral administration does pro-
tect photoreceptors. This appears to be due
specifically to the host immune response. Acti-
vated T cells have been shown to produce brain
derived neurotrophic factor (BDNF) in vitro
and in the CNS23 and autoimmune T cells have
been shown to protect axtomised neurons.24
Inflammation in the eye may also result in
upregulation of neurotrophic factors. Confir-
mation of this and the identification of particu-
lar factors requires further study.
A number of groups have reported short
term delay in loss of photoreceptor cells in the
rd mouse following AV mediated gene transfer
of a variety of genes but the mechanisms of the
delay have not yet been proved. Here we also
report a short term delay in the loss of
photoreceptor cells but show that the mech-
anism is that of an immune response. DiVer-
ences in the types and titres of recombinant
adenovirus used, variation in injection tech-
nique and the genetic background of animals,
the use of diVerent promoters (and thus
expression levels), and diVerences in the
method of morphological assessment make it
diYcult to compare the results presented here
with other studies involving AV.LacZ adminis-
tration to the rd mouse eye. However, in at least
one other system, intraocular AV.LacZ admin-
istration has resulted in a neuroprotective
eVect.25 While in some studies it appears that
administration of a vector carrying a reporter
gene is less eVective than vectors carrying
functional constructs, diVerences in immuno-
genicity may in part be responsible for this. For
instance, secreted gene products which contain
a Myc tag have been delivered15 and these may
be more immunogenic than an intracellular
reporter gene product. It would be interesting
to determine the relative importance of the
immune response to transgene and viral gene
Figure 2 Examples of sections taken close to the ONH region of 22 day old rd mice 10
days after intravitreal injection of either (A) 1 µl of PBS or (B) 1 µl of AV.LacZ (1×106
pfu). The 5 µm paraYn sections were counterstained with haematoxylin and eosin (40×
objective). Eyes injected with PBS had between one and two rows of photoreceptors in the
outer nuclear layer (ONL) whereas in some eyes injected with AV.Lac Z there were between
three and four rows of photoreceptors.
Figure 3 Comparison of rd ONL thickness in six groups of animals following intraocular
injection (io) of either PBS or AV.LacZ with and without T cell ablation as a result of
intraperitoneal injection (ip) of either PBS or monoclonal antibodies (mAb) specific for CD4
or CD8.The number of eyes in each treatment group (from 1 to 6) is 12, 6, 6, 8, 10, and 10
respectively. The scoring system was as follows: 0, a sparse row of photoreceptors; 1, a single row
of photoreceptors; 2, between one and two rows of photoreceptors; 3, between two and three rows
of photoreceptors, and so on.The data show the standard error of the mean ONL score. The
diVerence in ONL thickness between treatment groups 1, 2, and 3 is not statistically
significant. There are also no statistically significant diVerences in ONL thickness between
treatment groups 4, 5, and 6.There is, however, a significant diVerence between groups 1 and
4 (p> 0.01); 1 and 5 (p< 0.005); 1 and 6 (p< 0.001); 2 and 4 (p< 0.05); 2 and 5
(p<0.05); 2 and 6 (p<0.005); 3 and 4 (p<0.05); 3 and 5 (p<0.05); 3 and 6 (p<0.005).
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products. In order to exclude the possibility
that an immune response to vector and/or
transgene product is responsible for delaying
loss of photoreceptors in this mouse model it is
important to use controls with immunosup-
pression or an inactive “functional” gene.
Where the target cells are photoreceptors,
which are transduced by AV with an eYciency
of 2–3%, it is particularly important to demon-
strate the mechanism of rescue.
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